Third member of prestigious FDA panel resigns over approval of Biogen's Alzheimer's drug

www.cnbc.com
3 min read
fairly difficult
A third member of a key FDA panel has resigned over the agency's controversial decision to approve Biogen's new Alzheimer's drug, Aduhelm, CNBC has learned.
A sign for the Food and Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.

A third member of a key Food and Drug Administration advisory panel has resigned over the agency's controversial decision to approve Biogen's new Alzheimer's drug, Aduhelm, CNBC has learned.

Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School, said the agency's decision on Biogen "was probably the worst drug approval decision in recent U.S. history," according to his resignation letter obtained by CNBC.

"At the last minute, the agency switched its review to the Accelerated Approval pathway based on the debatable premise that the drug's effect on brain amyloid was likely to help patients with Alzheimer's disease," he wrote in resigning from the FDA's Peripheral and Central Nervous System Advisory Committee.

He wrote it was "clear" to him that the agency is not "presently capable of adequately integrating the Committee's scientific recommendations into its approval decisions."

"This will undermine the care of these patients, public trust in the FDA, the pursuit of useful therapeutic innovation, and the affordability of the health care system," he said.

Shares of Biogen surged 38%…
Berkeley Lovelace Jr.
Read full article